P-mab

P-mab is a first-in-class monoclonal antibody targeting cell-surface plectin (CSP), a cytolinker protein that is aberrantly mislocalized to the plasma membrane in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), ovarian carcinoma, and cholangiocarcinoma, while remaining cytoplasmic in normal tissues. Developed by Plectin Therapeutics in collaboration with the University of Virginia, P-mab functions by blocking the pro-tumorigenic activities of CSP, such as cell proliferation, migration, and invasion. Furthermore, CSP has been identified as an immune suppressor in the tumor microenvironment; therapeutic blockade with P-mab has been shown to restore anti-tumor immunity by promoting the infiltration of CD4+ and CD8+ T cells and reducing tumor burden. It is currently being evaluated in early-phase clinical trials (NCT05074472) for safety and feasibility in patients with CSP-positive solid tumors.

Other names

anti-CSP monoclonal antibodyanti-cell surface plectin monoclonal antibodyplectin-targeting monoclonal antibody